StreetAlpha.app
Home › Stocks › ARVN

Arvinas, Inc. (ARVN)

$6.82
▲ +0.74%
LAST CLOSE · NOV 17

Arvinas develops protein degrader medicines that aim to remove disease-causing proteins to treat cancer and neurological diseases. It last closed at $6.82 on Nov 17, up 0.74% on the day.

AI Auto Pilots
Is ARVN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$275.3M
−11.8% vs a year ago
Net income
−$9.5M
−3.5% margin
EPS (diluted)
−$0.08
Free cash flow
−$159.8M
−58.0% margin
Valuation
Market cap
$446.6M
65.5M shares
P/E
–
No P/E while losing money
Price to sales
1.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$88.0M
At Sep 30
Debt
$400K
At Sep 30
Shareholder equity
$513.8M
Buybacks
$74.1M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $46.7M$46.7MFY2021FY2022: $131.4M$131.4MFY2022FY2023: $78.5M$78.5MFY2023FY2024: $263.4M$263.4MFY2024FY2025: $262.6M$262.6MFY2025

From ARVN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated ARVN in the past 90 days, not enough for a consensus
Average 12-month target
$13.00
▲ 90.6% upside

Based on 1 analyst who set a price target on ARVN in the past 90 days. The average target is $13.00, with a high of $13.00 and a low of $13.00, compared with the last close of $6.82.

Low $13.00Avg $13.00High $13.00
Blue marker: last close $6.82
Highest target$13.00
Average target$13.00
Lowest target$13.00
Latest rating changes
HC Wainwright & Co.Maintained
Nov 3Buy$13
Evercore ISI GroupMaintained
Aug 10Buy$14
Wells FargoDowngrade
Aug 5Hold$11
WedbushMaintained
Aug 5Hold$12
BTIGReiterated
Aug 4Buy$18
DateFirmActionRatingPrice target
Nov 3HC Wainwright & Co.MaintainedBuy$13
Aug 10Evercore ISI GroupMaintainedBuy$14
Aug 5Wells FargoDowngradeHold$11
Aug 5WedbushMaintainedHold$12
Aug 4BTIGReiteratedBuy$18
Loading…

Technical Analysis

ARVN · as of the Nov 17 close · updated after every close
Downtrend

The stock is 5% below its 20 day and 10% below its 50 day average. It is 37% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 43). The nearest support is the swing low (Oct 14) at $6.74, and the nearest resistance the Pivot R1 at $6.95.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 5.7%/day
Key levels
$14.5152 week high+112.8%
$9.33200 day average+36.8%
$8.11100 day average+18.9%
$7.5250 day average+10.3%
$7.1820 day average+5.3%
$6.96Swing high (Nov 11)+2.1%
$6.95Pivot R1+1.9%
$6.82Last close
$6.74Swing low (Oct 14)−1.2%
$6.70Pivot−1.8%
$6.57Pivot S1−3.7%
$6.3352 week low−7.2%
Indicators
RSI (14)42.63Middle of its rangeNeutral
MACD-0.23Below its signal lineBearish
Stochastic27.8Middle of its rangeNeutral
ADX (14)19.7No clear trend
Williams %R-71.2Oversold below −80, overbought above −20Neutral
CCI (20)-81.1Oversold below −100, overbought above 100Neutral
Rate of change−3.8%Change over 10 sessionsBearish
ATR (14)$0.39Typical daily range, 5.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ARVN

What happened before

See how ARVN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ARVN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ARVN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ARVN in the last 90 days.

Loading…

See today’s whale options flow across the market →

ARVN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲107 buying vs 82 selling
  • ▲Held by funds +5.4 pts
  • ▼Funds holding -3
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding198201−1.5%
In funds' top 1012−50.0%
Held by funds91.3%85.9%+5.4 pts
New / increased24 / 8332 / 79−3.6%
Reduced / sold out54 / 2852 / 39−9.9%
Put/call ratio1.591.35+17.6%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ARVN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARVN is in one of them and how their past ARVN trades turned out.

ARVN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ARVN in an article yet. Here's the latest on the wider market.

About Arvinas

Arvinas is a biotechnology company based in New Haven, Connecticut. It develops medicines that use targeted protein degradation, a method that removes disease-causing proteins from cells by using the body's own protein disposal system. Its drug candidates focus mainly on cancer and neurological diseases such as Parkinson's disease, and several are in clinical trials with patients. The company also works with larger drug makers, including Pfizer and Genentech, on early-stage research.

Headquarters
New Haven, CT
Founded
2013